Vitamin c and chemo: new hope for Hard-to-Treat sarcomas?

NCT ID NCT04634227

Ongoing Disease control Sponsor: University of Iowa Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether adding high-dose vitamin C (ascorbate) to the chemotherapy drug gemcitabine can help adults with advanced soft tissue or bone sarcoma that cannot be surgically removed or has spread. About 30 participants will receive the combination intravenously. The main goal is to see how many patients have stable disease or better after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and high-dose vitamin C (ascorbate)
What this could lead to: If it works, this could point toward a new combination treatment to slow the growth of advanced sarcomas that have not responded to other therapies.
What could go wrong: This is a very early, small pilot study with only 30 participants. It is not designed to prove effectiveness, and the high-dose vitamin C may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone cancer bone sarcoma metastatic carcinoma in the bone sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE SARCOMA METASTATIC BONE TUMOR SARCOMA SOFT TISSUE SARCOMA UNRESECTABLE SOFT TISSUE SARCOMA

Contacts and locations

Show contact details

Locations

John

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.